|
ATBC Study
|
ZIA CP010195-03031
|
$1,161,432
|
$174,215
|
N/A
|
DCEG (NCI)
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$20,400
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$10,200
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$20,171
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$33,922
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$644,762
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Linxian nutrition intervention trial follow-up study
|
ZIA CP000112-00377
|
$254,770
|
$229,293
|
Abnet, Christian
|
DCEG (NCI)
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185-10318
|
$18,664
|
$18,664
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Golestan Cohort Study
|
ZIA CP000185-10361
|
$31,091
|
$31,091
|
Abnet, Christian
|
DCEG (NCI)
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-04S1
|
$94,087
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-04
|
$382,753
|
$382,753
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
$23,241
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-04
|
$737,200
|
$110,580
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
1K08CA218420-01
|
$177,120
|
$177,120
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
$317,765
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Prospective Study of Human Oral Microbiome and Pancreatic Cancer Risk
|
5R01CA164964-04
|
$468,512
|
$468,512
|
AHN, JIYOUNG
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
|
2R01CA134633-05
|
$540,493
|
$540,493
|
AHRENS, ERIC
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-04
|
$398,393
|
$398,393
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
5R01CA172741-05
|
$279,793
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Role of Nix in pancreatic ductal adenocarcinoma
|
5F30CA200240-02
|
$49,044
|
$49,044
|
ALAGESAN, BRINDA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-04
|
$1,367,856
|
$205,178
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Mesothelin-targeted immunotoxins in Pancreatic Cancer
|
ZIA BC 011652
|
$664,209
|
$664,209
|
Alewine, Christine
|
CCR (NCI)
|
|
Clinical Support
|
ZIE BC 011653
|
$34,958
|
$10,488
|
Alewine, Christine
|
CCR (NCI)
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
|
1F30CA220847-01
|
$49,044
|
$49,044
|
ALI, MOIEZ
|
DUKE UNIVERSITY
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-04
|
$584,480
|
$584,480
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
5R01CA182076-04
|
$349,513
|
$349,513
|
ALLEN, PETER
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-03
|
$378,171
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN
|
|
MYC is a critical downstream effector in KRAS-driven pancreatic cancer
|
5F32CA192769-03
|
$60,990
|
$60,990
|
ALLEN-PETERSEN, BRITTANY
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-02
|
$520,564
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
$1,425
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
$26,456
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
5R01CA169134-05
|
$312,942
|
$312,942
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$755,842
|
$151,168
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
|
1R21CA213114-01A1
|
$170,738
|
$170,738
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Automated, Augmented Reality High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
3R01CA181275-03S1
|
$497,433
|
$497,433
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-04
|
$1,088,646
|
$1,088,646
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-04
|
$688,666
|
$688,666
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Bitter Melon Component and Colon Cancer Prevention
|
5R01CA190291-04
|
$544,710
|
$544,710
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S1
|
$56,922
|
$10,246
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S2
|
$165,708
|
$29,827
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
5UM1CA173642-05
|
$2,260,718
|
$406,929
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-04
|
$637,150
|
$95,573
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
LINE-1 genotoxicity and cytotoxicity and its relevance to cancer
|
1F30CA221175-01
|
$49,044
|
$16,185
|
ARDELJAN, DANIEL
|
JOHNS HOPKINS UNIVERSITY
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-08
|
$1,192,222
|
$858,400
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
Reversing Cellular immortality in cancer
|
5R35CA197563-03
|
$962,884
|
$962,884
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
$17,500
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
$248,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
T Cell Alternative p38 Activation Pathway
|
ZIA BC 010774
|
$559,148
|
$279,574
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
$338,270
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
$6,250
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
Total relevant funding to Digestive Diseases for this search: $532,523,882
|